ADC Therapeutics (ADC Therapeutics) Ending Cash Position : $278.60 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Ending Cash Position?

ADC Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was $278.60 Mil.

ADC Therapeutics's quarterly Ending Cash Position declined from Jun. 2023 ($347.51 Mil) to Sep. 2023 ($310.41 Mil) and declined from Sep. 2023 ($310.41 Mil) to Dec. 2023 ($278.60 Mil).

ADC Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($466.54 Mil) to Dec. 2022 ($326.44 Mil) and declined from Dec. 2022 ($326.44 Mil) to Dec. 2023 ($278.60 Mil).

ADC Therapeutics Ending Cash Position Historical Data

The historical data trend for ADC Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Ending Cash Position Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

115.55

439.20

466.54

326.44

278.60

ADC Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															326.44	310.55	347.51	310.41	278.60

ADC Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ADC Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	326.441	+	-47.843
	=	278.60

ADC Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	310.407	+	-31.809
	=	278.60

ADC Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.